The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

India’s drug regulator has approved Eli Lilly and Company’s diabetes and obesity drug Mounjaro in a KwikPen presentation, the ...

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss ...

Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.

The molecule reviewed in the October 17th press release demonstrated 80% bioavailability relative to ... provided a look at new preclinical data for a glucagon-like peptide-1 (GLP-1) incretin ...

OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and ... and a weekly injectable variant of the same molecule, ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to ...

Glucagon with added rapid-acting insulin. ... "We are talking about 5 nanograms per unit of insulin, which means that the solution contains 1 glucagon molecule per 420 insulin molecules.

Altimmune is a single-molecule company currently trading at a $0.5 billion market cap with a favorable risk-reward profile. The company's existence depends almost entirely on the outcome of the ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...